Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab biosimilar - Zydus Cadila

Next Previous
Drug Profile

Pertuzumab biosimilar - Zydus Cadila

Alternative Names: ZRC-3277

Latest Information Update: 24 May 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zydus Cadila
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III HER2 positive breast cancer

Most Recent Events

  • 20 Mar 2024 Zydus Lifesciences Limited completes a phase III trials in HER2-positive breast cancer (Combination therapy, Metastatic disease, Late-stage disease, In adults, In the elderly) in India (IV) (NCT05283837)
  • 20 Mar 2024 Pharmacokinetics, Efficacy, adverse events and immunogenicity data from phase-III trial in HER2-positive breast cancer presented at the 14th European Breast Cancer Conference (EBCC-2024)
  • 20 Mar 2024 Zydus Lifesciences completes enrolment in phase-III trial for HER2-positive breast cancer (Combination therapy, Metastatic disease, Late-stage disease, In adults, In the elderly) in India (IV) before March 2024 (NCT05283837)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top